Wolfe Research analyst Mike Polark downgraded Silk Road Medical to Peer Perform from Outperform without a price target. The analyst sees "good growth and more beats" as likely but says the stock’s expanded relative valuation leaves the short-run risk/reward "feeling more balanced." Silk Road ‘s relative valuation has flipped from a discount to premium, the analyst tells investors in a research note.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on SILK:
- Silk Road Medical to Report Fourth Quarter and Full Year 2022 Financial Results on February 28, 2023
- Silk Road Medical price target raised to $70 from $60 at Argus
- Silk Road Medical to Present at the 41st Annual J.P. Morgan Healthcare Conference
- Citi ups Silk Road target, opens ‘Positive Catalyst Watch’
